Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Japanese and Chinese Adults With Uncontrolled Partial-Onset Seizures With or Without Secondary Generalization

Trial Profile

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Japanese and Chinese Adults With Uncontrolled Partial-Onset Seizures With or Without Secondary Generalization

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lacosamide (Primary) ; Antiepileptic drugs
  • Indications Partial epilepsies
  • Focus Registrational; Therapeutic Use
  • Sponsors UCB Pharma SA
  • Most Recent Events

    • 20 May 2021 Results assessing cost-effectiveness and budget impact of perampanel versus lacosamide by using data from two studies including this study presented at the 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 04 Jul 2016 According to an Daiichi Sankyo media release, the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted approval for Lacosamide (VIMPAT) as an adjunctive therapy in the treatment of partial onset seizures with or without secondary generalization in adult patients with epilepsy who have not obtained sufficient response to other antiepileptic drugs.
    • 21 Dec 2015 Results of this trial were presented at the 2015 Annual Meeting of the American Epilepsy Society, according to a Daiichi Sankyo media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top